The 2024 Specialty Pharmacy Manufacturer Perceptions Report
Cutting-Edge Insights from Curatio Advisors
The 2024 Specialty Pharmacy Pharma Engagement Perceptions Report provides exclusive, data-driven analysis of specialty pharmacy engagement dynamics, offering actionable strategies for manufacturers to optimize their approach and drive better patient outcomes. We surveyed and interviewed executives from the major SPs, exploring the effectiveness of manufacturer engagement in terms of relationship management and business productivity.
Key Features:
- Exclusive Proprietary Data: Unavailable anywhere else, based on direct industry research.
- Comprehensive Strategies: Analysis of pharmacy relationship management and approaches for business productivity.
- Actionable Insights: Tailored for contracting, account management, brand, and market access teams.
- Patient-Focused: Align your strategies with best practices to enhance access and outcomes.
Manufacturers Evaluated:
Ten (10) specialty pharmaceutical manufacturers were selected based on publicly available revenue information from 2022 specialty drug sales. These manufacturers included:
Respondent SPs were asked to name or call out other pharma or biotech manufacturers that stand out as having done an exceptional job engaging with their SP:
Methodology
A Manufacturer Specialty Pharmacy Survey and Assessment Framework was developed to assess a peer group of Pharma and Biotech manufacturers’ engagement and approach with the specialty pharmacy channel. This framework consisted of the collection of market insights through surveys and interviews. A standardized survey framework was leveraged to gain consistent structured feedback from respondents. Live telephonic and in-person interviews were conducted by Curatio Advisors staff. The survey and interview guide included a series of questions across the following perspectives to include:
- Manufacturer relationship and account management
- Quarterly Business Review Process and Data shared during QBRs
- Purchase Price Discount Agreements with manufacturers
- Services and Data Agreement with manufacturers
- Innovation
- Impact on Brand Loyalty
This framework enabled an assessment of manufacturers’ SP engagement efforts. Manufacturer engagement with the SPs was assessed based on two axes, Business Productivity and Relationship Management. Manufacturers were rated and ranked based on sub-factors within each of these two major categories. These sub-factors are listed below:
Relationship Management
- Account Management Effectiveness (Quality)
- Overall ease of working together
- Responsiveness
- Overall Relationship Management
Business Productivity
- Contracting Effectiveness
- Organizational Consistency
- Flexibility and Innovativeness
- Overall Business Relationship
Licensing Options
Corporate License + PPT:
$12,500
(Unlimited use. Includes PowerPoint file. Immediate download.)
Corporate License:
$10,000
(Unlimited use. Immediate download.)
Department License
$6,000
(For 2-8 employees. Immediate download.)
Single-User License:
$3,000
Strict eligibility: Approval required
Customized Leadership Presentation and Workshop:
$15,250
(Available as add-on for Corporate License + PPT purchasers only)
Curatio Scientia Advisors releases the “2023 Patient Access: State Legal and Regulatory Environment Survey”
Given the dynamic nature of state government activity we sought to validate the following:
- Patient access to prescription drug therapy is greatly affected by various state and local policy and regulatory parameters.
- There is no formalized process or aggregating compendium, at the state level, specifically monitoring policy and regulatory parameters that impact patient access to, and affordability of, drug therapies.
- Timely insights into legislation and regulations pertaining to patient access, particularly for high-cost drug therapies will enable more effective decisions regarding the patient’s journey and drug product lifecycle.